Scarica l'app Stockscreener
40.95
2.80%
-1.18
Pre-mercato:
40.58
-0.37
-0.90%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 6,785 Shares of Stock - MarketBeat
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CFO Sells 1,014 Shares of Stock - MarketBeat
Jula Inrig Sells 7,215 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
FDA milestone vests shares for Travere Therapeutics (NASDAQ: TVTX) CRO - Stock Titan
Travere (TVTX) legal chief sells 51,500 shares after option exercises - Stock Titan
Travere Therapeutics (TVTX) CMO logs PSU vesting and routine share sales - Stock Titan
Travere therapeutics: Chief legal officer sells $2.13M in TVTX stock - Investing.com
Travere therapeutics CEO Dube sells $2.63 million in TVTX stock By Investing.com - Investing.com Canada
Inrig Jula of Travere Therapeutics sells $345k in TVTX stock - Investing.com Canada
Travere Therapeutics Inc SEC Filings - Stock Titan
A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI’s Landmark FDA Approval For FSGS - Yahoo Finance
Heerma Peter, chief commercial officer, sells $302k in Travere Therapeutics (TVTX) - Investing.com
Travere Therapeutics: Re-Rating Potential As Filspari Wins Full Approval (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics sees its composite rating rise to 97 - MSN
FDA approval for Travere's drug expands reach to broader rare kidney disease patients - MSN
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 14, 2026 - BioSpace
Travere Therapeutics TVTX Stock 2026 Outlook: Buy Rating Holds After FDA Approval of FILSPARI for FSGS - International Business Times Australia
Travere Therapeutics (TVTX) Shares Surge 33% in Trading - GuruFocus
TVTX (NASDAQ) Form 144 shows proposed resale after PRSU vesting, brokered by Morgan Stanley - Stock Titan
TVTX (NASDAQ: TVTX) files Form 144 to resell 7,215 RSU shares - Stock Titan
Elizabeth Reed reports sales of TVTX common stock (NASDAQ: TVTX) in Form 144 - Stock Titan
TVTX (NASDAQ: TVTX) Form 144 lists RSU vesting and planned share sales - Stock Titan
TVTX Maintained by Citigroup -- Price Target Raised to $53.00 - GuruFocus
Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease - MedCity News
Travere’s Filspari approved for rare kidney disease FSGS - BioWorld News
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
Travere Therapeutics (TVTX) Surges 32.5% in Market Performance - GuruFocus
Affiliate proposes sale of 9,052 TVTX shares via Morgan Stanley (TVTX) - Stock Titan
37,500-share planned sale at TVTX (NASDAQ: TVTX) — insider notice - Stock Titan
Travere Therapeutics Stock Skyrockets On Highly Anticipated FDA Approval - Investor's Business Daily
32,750-share Option Exercise Filed by TVTX (NASDAQ: TVTX) - Stock Titan
Stifel raises Travere Therapeutics price target on Filspari approval - Investing.com
Stifel raises Travere Therapeutics price target on Filspari approval By Investing.com - Investing.com Australia
Sandra Calvin insider sale reported (NASDAQ: TVTX) — 4,333 shares sold - Stock Titan
Travere Therapeutics (TVTX) Sees 43% Surge After FDA Approval - GuruFocus
TVTX Maintained by Guggenheim -- Price Target Raised to $54.00 - GuruFocus
FDA approves Filspari for FSGS, Travere’s second indication By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 42.2 USD By Investing.com - Investing.com Australia
TVTX Maintains Rating by Wedbush -- Price Target Raised to $44 - GuruFocus
TVTX Maintained by Canaccord Genuity -- Price Target Raised to $56 - GuruFocus
TVTX Stock Jumps As FDA Approval Fuels Bullish Momentum - StocksToTrade
Ligand (LGND) Partners with Travere on FDA Approval for Filspari - GuruFocus
Travere wins long-awaited approval for kidney disease drug - BioPharma Dive
Travere Therapeutics (TVTX) Stock Rockets 44% on Groundbreaking FSGS Treatment Approval - MEXC
TVTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $47 - GuruFocus
TVTX Stock Jumps As FILSPARI Wins Full FDA Approval - timothysykes.com
Travere Therapeutics (NASDAQ:TVTX) Given New $56.00 Price Target at Canaccord Genuity Group - MarketBeat
Travere Therapeutics Hits New 1-Year High After Analyst Upgrade - National Today
HC Wainwright Reiterates Buy Rating for Travere Therapeutics - National Today
Travere Therapeutics (TVTX) Stock Surges 44% After FDA Approves FILSPARI for Rare Kidney Disease - MEXC
Avanos Medical, Travere Therapeutics, Globalstar And Other Big Stocks Moving Higher On Tuesday - Benzinga
Travere Therapeutics stock hits 52-week high at 42.2 USD - Investing.com
Travere Therapeutics Stock Soars 33% After FDA Approves FILSPARI as First Drug for Rare Kidney Disease FSGS - International Business Times Australia
Travere’s Filspari wins landmark US approval - The Pharma Letter
Guggenheim Raises Travere Therapeutics (NASDAQ:TVTX) Price Target to $54.00 - MarketBeat
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):